A phase III, randomized trial of docetaxel plus carboplatin (TP) versus epirubicin plus cyclophosphamide followed by docetaxel (EC-T) as adjuvant treatment for ...
... (CBCSG-036): A randomized, controlled, multicenter trial. Cancer. 2019 ... Keywords: breast cancer; clinical trial; concurrent; estrogen ...
People also ask
What is the life expectancy with Xeloda?
How bad is chemo for triple negative breast cancer?
What is the success rate of capecitabine for breast cancer?
Can you take Herceptin and Perjeta without chemotherapy?
Jun 1, 2020 · Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, ...
This prospective, open-label, multicenter, randomized, phase III clinical trial was conducted at 35 medical institutions in China within the CBCSG (Appendix ...
Mar 20, 2019 · ... (CBCSG‐036): A randomized, controlled, multicenter trial FREE - In Google Play. VIEW · American Cancer Society ...
People also search for
Related treatments
For informational purposes only. Consult your local medical authority for advice.
Mar 12, 2022 · 73.0%, p = 0.03, [20]. Similarly, the CBCSG-010 trial, which added capecitabine concurrently with the standard chemotherapy (3XAC-3TX vs. 3FAC-3 ...
Jan 13, 2024 · Seven meta-analyses summarizing the role of capecitabine in breast cancer adjuvant and neoadjuvant chemotherapy have been performed, six of ...
Jan 15, 2009 · As one of the second objectives of the CBCSG–001 trial (China multicenter study of sentinel node biopsy substituting axillary node dissection), ...
The present study focused on the prospective comparison of the performance between OSNA and touch imprint cytology (TIC). Methods. The retrieved SLNs were ...
Estrogen receptor (ER) and human epidermal growth factor 2 (HER2) expression guide the use of neoadjuvant chemotherapy (NACT) in patients with early breast ...
In response to a legal request submitted to Google, we have removed 1 result(s) from this page. If you wish, you may read more about the request at LumenDatabase.org. |